Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD

European Journal of Clinical Investigation

Volumn 42, Issue 4, 2012, Pages 419-426

  Kanazawa, Hiroshi ^a   Tochino, Yoshihiro ^a   Asai, Kazuhisa ^a   Ichimaru, Yukikazu ^a   Watanabe, Tetsuya ^a   Hirata, Kazuto ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bronchoscopic microsampling technique; High resolution computed tomographic scans; Human polymorphonuclear elastase; Interleukin 8

Indexed keywords

ELASTASE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 8;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRONCHOSCOPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EPITHELIUM; EPITHELIUM LINING FLUID; FEMALE; HUMAN; LUNG FUNCTION; MALE; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SMOKING; TISSUE WATER; VALIDITY;

AGED; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HMGB1 PROTEIN; HUMANS; INTERLEUKIN-8; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; RESPIRATORY MUCOSA; SMOKING; STATISTICS AS TOPIC; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84858277649     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02598.x     Document Type: Article

References (33)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
2. Hogg JC, Chu FSF, Tan WC, Sin DD, Patel SA, Pare PD et al. Survival after lung volume reduction in chronicobstructive pulmonary disease. Insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-9.
3. Rice A, Nicholson AG. The pathologist's approach to small airways disease. Histopathology 2009;54:117-33.
4. Yoshida T, Tuder RM. Pathology of cigarette smoke-induced chronic obstructive pulmonary disease. Physiol Rev 2007;87:1047-82.
5. Larsson K. Aspects on pathophysiological mechanisms in COPD. J Intern Med 2007;262:311-40.
6. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1) nuclear weapon in the immune arsenal. Nat Rev Immunol 2005;5:331-42.
7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
8. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002;170:3273-8.
9. Yang H, Ochani M, Li J, Qiang X, Tanovic M, Harris HE et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci 2004;101:296-301.
10. Ueno H, Matsuda T, Hashimoto S, Amaya F, Kitamura Y, Tanaka M et al. Contribution of high mobility group protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004;170:1310-6.
11. Ogawa EN, Ishizaka A, Tasaka S, Koh H, Ueno H, Amaya F et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med 2006;174:400-7.
12. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:917-27.
13. Kodama T, Kanazawa H, Tochino Y, Kyoh S, Asai K, Hirata K. A technological advance comparing epithelial lining fluid from different regions of the lung in smokers. Respir Med 2009;103:35-40.
14. Watanabe M, Ishizaka A, Ikeda E, Ohashi A, Kobayashi K. Contributions of bronchoscopic microsampling in the supplemental diagnosis of small peripheral lung carcinoma. Ann Thorac Surg 2003;76:1668-73.
15. Kanazawa H, Kodama T, Asai K, Matsumura S, Hirata K. Increased levels of Nε-(carboxymethyl)lysine in epithelila lining fluid from peripheral airways in patients with chronic obstructive pulmonary disease: a pilot study. Clin Sci 2010;119:143-9.
16. Ishizaka A, Watanabe M, Yamashita T, Ogawa Y, Koh H, Hasegawa N et al. New bronchoscopic microsample probe to measure the biochemical constituents in epithelial lining fluid of patients with acute respiratory distress syndrome. Crit Care Med 2001;29:896-8.
17. Ishizaka A, Matsuda T, Albertine KH, Koh H, Tasaka S, Hasegawa N et al. Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2004;286:L1088-94.
18. Nakano Y, Tasaka S, Saito F, Yamada W, Shiraishi Y, Ogawa Y et al. Endothelin-1 level in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology 2007;12:740-3.
19. Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol 1982;33:379-87.
20. Schmidt AM, Yan SD, Yan SF, Stem DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001;108:949-55.
21. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-69.
22. Wu L, Ma Li, Nicholson LFB, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med 2011;105:329-36.
23. Rendon-Mitchell B, Ochani M, Li J, Han J, Wang H, Yang H et al. IFN-γ induces high mobility group box 1 protein release partly through a TNF-dependent mechanism. J Immunol 2003;170:3890-7.
24. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A et al. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999;126:389-92.
25. Taniguchi N, Kawahara K, Yone K, Hashiguchi M, Goto M. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003;48:971-81.
26. Hamada N, Maeyama T, Kawaguchi T, Yoshimi M, Fukumoto J, Yamada M et al. The role of high mobility group box 1 in pulmonary fibrosis. Am J Respir Crit Care Med 2008;39:440-7.
27. Di Stefano A, Capelli A, Lusuardi M, Balbo P, Vecchio C, Maestrelli P et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158:1277-85.
28. Sappington PL, Yang R, Yang H, Tracey KJ, Delude RL, Fink MP. HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 2002;123:790-802.
29. Andersson U, Wang H, Palmblad K, Aveberger A-C, Bloom O, Erlandsson-Harris H et al. High mobility group box 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000;21:565-70.
30. Youn JH, Oh YJ, Kim ES, Choi JE, Shin J-S. High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes. J Immunol 2008;180:5067-74.
31. Sha Y, Zmijewski J, Xu Z, Abraham E. HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531-7.
32. Yang H, Wang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukoc Biol 2005;78:1-8.
33. Hogg JC, Chu F, Utokaparch S, Woods R, Elliot WM, Buzatu L et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53.